Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Anti-TGF-β/PD-L1 bispecific antibody promotes T cell infiltration and exhibits enhanced antitumor activity in triple-negative breast cancer
Ming Yi, Yuze Wu, Mengke Niu, et al.
Journal for ImmunoTherapy of Cancer (2022) Vol. 10, Iss. 12, pp. e005543-e005543
Open Access | Times Cited: 95

Showing 1-25 of 95 citing articles:

Advances in immunotherapy for triple-negative breast cancer
Yang Liu, Yueting Hu, Jinqi Xue, et al.
Molecular Cancer (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 108
Recent advances in targeted strategies for triple-negative breast cancer
Shuangli Zhu, Yuze Wu, Bin Song, et al.
Journal of Hematology & Oncology (2023) Vol. 16, Iss. 1
Open Access | Times Cited: 103
Exploiting innate immunity for cancer immunotherapy
Ming Yi, Tianye Li, Mengke Niu, et al.
Molecular Cancer (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 78
Targeting cytokine and chemokine signaling pathways for cancer therapy
Ming Yi, Tianye Li, Mengke Niu, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 49
Synergistic efficacy of simultaneous anti-TGF-β/VEGF bispecific antibody and PD-1 blockade in cancer therapy
Mengke Niu, Ming Yi, Yuze Wu, et al.
Journal of Hematology & Oncology (2023) Vol. 16, Iss. 1
Open Access | Times Cited: 46
Polysaccharides regulate Th1/Th2 balance: A new strategy for tumor immunotherapy
Qihang Shang, Xiaoyun Yu, Qi Sun, et al.
Biomedicine & Pharmacotherapy (2023) Vol. 170, pp. 115976-115976
Open Access | Times Cited: 44
T-cell infiltration and its regulatory mechanisms in cancers: insights at single-cell resolution
Wenhui Yang, Shimao Liu, Mengyun Mao, et al.
Journal of Experimental & Clinical Cancer Research (2024) Vol. 43, Iss. 1
Open Access | Times Cited: 23
CAR-NK cells for cancer immunotherapy: recent advances and future directions
Tianye Li, Mengke Niu, Weijiang Zhang, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 22
Advances and Challenges in Targeting TGF-β Isoforms for Therapeutic Intervention of Cancer: A Mechanism-Based Perspective
David Danielpour
Pharmaceuticals (2024) Vol. 17, Iss. 4, pp. 533-533
Open Access | Times Cited: 18
Global status and attributable risk factors of breast, cervical, ovarian, and uterine cancers from 1990 to 2021
Tianye Li, Haoxiang Zhang, Mengyi Lian, et al.
Journal of Hematology & Oncology (2025) Vol. 18, Iss. 1
Open Access | Times Cited: 5
The application and research progress of anti-angiogenesis therapy in tumor immunotherapy
Jingyao Tu, Hang Liang, Chunya Li, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 29
Identification of MTHFD2 as a prognostic biomarker and ferroptosis regulator in triple-negative breast cancer
Hao Zhang, Shuangli Zhu, Haiting Zhou, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 28
Mechanisms of CD8+ T cell exclusion and dysfunction in cancer resistance to anti-PD-(L)1
Keywan Mortezaee, Jamal Majidpoor
Biomedicine & Pharmacotherapy (2023) Vol. 163, pp. 114824-114824
Open Access | Times Cited: 24
Nanoparticle-based immunoengineering strategies for enhancing cancer immunotherapy
Bao-Toan Nguyen Dang, Taeg Kyu Kwon, Sooyeun Lee, et al.
Journal of Controlled Release (2023) Vol. 365, pp. 773-800
Closed Access | Times Cited: 22
Targeting tumor-infiltrating tregs for improved antitumor responses
Diyuan Qin, Yugu Zhang, Pei Shu, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 14
The enhanced antitumor activity of bispecific antibody targeting PD-1/PD-L1 signaling
Tianye Li, Mengke Niu, Jianwei Zhou, et al.
Cell Communication and Signaling (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 14
Tumor battlefield within inflamed, excluded or desert immune phenotypes: the mechanisms and strategies
Siwei Zheng, Wenwen Wang, Lesang Shen, et al.
Experimental Hematology and Oncology (2024) Vol. 13, Iss. 1
Open Access | Times Cited: 13
Breaking Barriers: The Promise and Challenges of Immune Checkpoint Inhibitors in Triple-Negative Breast Cancer
Sawsan Sudqi Said, Wisam Nabeel Ibrahim
Biomedicines (2024) Vol. 12, Iss. 2, pp. 369-369
Open Access | Times Cited: 8
Bispecific antibodies targeting CTLA-4: game-changer troopers in cancer immunotherapy
Pooya Farhangnia, Shamim Mollazadeh Ghomi, Mahzad Akbarpour, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 20
Bispecific antibody targeting TGF-β and PD-L1 for synergistic cancer immunotherapy
Tianye Li, Xinrun Wang, Mengke Niu, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 20
Nivolumab plus ipilimumab combination therapy in cancer: Current evidence to date
Marzieh Nikoo, Fatemeh Rabiee, Hossein Mohebbi, et al.
International Immunopharmacology (2023) Vol. 117, pp. 109881-109881
Closed Access | Times Cited: 17
Indoleamine 2,3-dioxygenase 1 in circumventing checkpoint inhibitor responses: Updated
Arian Charehjoo, Jamal Majidpoor, Keywan Mortezaee
International Immunopharmacology (2023) Vol. 118, pp. 110032-110032
Closed Access | Times Cited: 16
Vascular normalization: reshaping the tumor microenvironment and augmenting antitumor immunity for ovarian cancer
Ping Yu, Yaru Wang, Dahai Yuan, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 15
Combination of novel oncolytic herpesvirus with paclitaxel as an efficient strategy for breast cancer therapy
Xinyue Deng, Yinan Shen, Ming Yi, et al.
Journal of Medical Virology (2023) Vol. 95, Iss. 5
Open Access | Times Cited: 13
Bispecific antibodies revolutionizing breast cancer treatment: a comprehensive overview
Huanrong Lan, Min Chen, Shi-Ya Yao, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 13
Page 1 - Next Page

Scroll to top